Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    " May 06, 2009":" June 05, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" May 06, 2009":" June 05, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
2 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
3 Unknown  Raltegravir in the Swiss HIV Cohort Study
Condition: HIV Infection
Intervention: Drug: Raltegravir
4 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
5 Completed Glutathione and Its Precursors in HIV-Infected Patients
Condition: HIV Infection
Intervention: Dietary Supplement: Glutathione precursors
6 Withdrawn PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Interventions: Drug: TMC589337 40 mg;   Drug: TMC589337 100 mg;   Drug: TMC589337 200 mg;   Drug: TMC589337 400 mg;   Drug: TMC589354 40 mg;   Drug: TMC589354 100 mg;   Drug: TMC589354 200 mg;   Drug: TMC589354 400 mg;   Drug: TMC589337 AA mg;   Drug: TMC589354 BB mg;   Drug: TMC589337 CC mg;   Drug: TMC589354 DD mg;   Drug: TMC589337 EE mg;   Drug: TMC589354 YY mg;   Drug: TMC310911 300 mg;   Drug: TMC310911 600 mg;   Drug: Placebo
7 Completed
Has Results
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
Condition: HIV Infections
Interventions: Drug: Nevirapine Immediate Release (IR);   Drug: Nevirapine Extended Release (XR)
8 Unknown  HIV and Kidney Function Study
Conditions: HIV Infections;   AIDS
Intervention:
9 Active, not recruiting New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
Condition: HIV Infections
Interventions: Other: PHI-patients;   Other: CHI-patients
10 Completed Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients
Conditions: HIV Infections;   COPD
Intervention:
11 Completed
Has Results
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Atazanavir (ATV) 300 mg;   Drug: Atazanavir (ATV) 400 mg;   Drug: Ritonavir (rtv) 100 mg;   Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs);   Drug: Etravirine (ETR) 200 mg;   Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
12 Completed
Has Results
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
13 Completed
Has Results
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)
14 Completed Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Condition: HIV
Interventions: Dietary Supplement: Vitamin D;   Drug: No supplementation
15 Completed Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV
Conditions: HIV;   Acquired Immunodeficiency Syndrome;   Cardiovascular Diseases
Interventions: Behavioral: Exercise Program;   Behavioral: Control Group
16 Completed Examining Hair to Determine Tenofovir Exposure
Condition: HIV
Intervention: Drug: Tenofovir Disoproxil Fumarate
17 Unknown  Exercise for Patients With HIV Infections
Conditions: HIV Infections;   Lipodystrophy;   Inflammation
Intervention: Behavioral: Exercise
18 Completed
Has Results
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
Condition: HIV-1 Infection
Interventions: Drug: darunavir;   Drug: ritonavir;   Drug: zidovudine;   Drug: lamivudine;   Drug: abacavir
19 Withdrawn Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Condition: HIV-1 Infections
Interventions: Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
20 Completed Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
Conditions: Human Immunodeficiency Virus;   Chronic Hepatitis C
Interventions: Drug: pegylated interferon-alpha (Pegasys);   Drug: ribavirin (COPEGUS)

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.